Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells

By W. Zou, V. Machelon, A. Coulomb-L'Hermin, J. Borvak, F. Nomé, T. Isaeva, Shuang Wei, R. Krzysiek, I. Durand‐Gasselin, Alan Gordon and 6 more. Nature Medicine, 2001

711 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/c3721f958ea5d39d1bc2baf430f8193d0b93b5d7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. W. Zou
2. D. Gabrilovich
3. Lieping Chen
4. D. Munn
5. A. Mellor
6. P. Rodriguez
7. Augusto Ochoa
8. George Coukos

Citations in the corpus

• B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma (2006, methodology): “These data provide mechanisms for how tumor environmental IL-6 and IL-10 induce immune dysfunction.”
• Cancer and the chemokine network (2004, background): “In ovarian cancer, tumour cell production of the chemokine CXCL12 can weaken immunity by attracting and encouraging the survival of CXCR4-expressing dendritic-cell precursor-2 (preDC2) cells, and by altering preDC1 distribution, immunity and stimulation of fibrosi”
• Ido expression by dendritic cells: tolerance and tryptophan catabolism (2004, background): “It is not yet known whether the IDO-expressing APCs in human tumour-draining lymph nodes are also plasmacytoid DCs; however, plasmacytoid DCs are well documented in human tumour”
• CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer (2004, neutral): “that suppress T-cell–mediated antitumor immunity (12).”
• Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. (2005, background): “Ascites that is present within the vicinity and drainage of the tumor might very likely represent the milieu of the tumor environment (36).”
• Plasmacytoid dendritic cells in immunity (2004, background): “, and CXCR4 is involved in pDC migration in vivo , at least into tumors”
• PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations (2016, background): “The association between tumor-infiltrating T cells (TILs), IFN-g signaling genes, and PD-L1 expression suggests that effector T cell–derived IFN-g contributes to high levels of PD-L1 expression in the tumor microenvironment (31).”
• Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (2003, background): “Suppression of MDC differentiation and function in cancer patients may contribute to inhibition of immune responses and cancer progressio”
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival (2004, background): “Ovarian cancers produce CXCL12, which mediates the trafficking of plasmacytoid dendritic cells to tumor”
• VEGF-targeted therapy: mechanisms of anti-tumour activity (2008, background): “Factors released from the tumour microenvironment, including VEGF, stimulate recruitment of immature DCs from the bone marrow and peripheral tissues to sites of tumour growt”